Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1113 | Ganoderic acid DM |
| Ganoderic acid DM is an antiandrogenic osteoclastogenesis inhibitor, it especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), this suppression leads to the inhibition of dendritic cell-specific transmembrane protein (DC-STAMP) expression and reduces osteoclast fusion. Ganoderic acid DM has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease, it may an alternative agent for the treatment of advanced prostate cancer. | |
| BCN1127 | 8-Hydroxyodoroside A |
| 1. An antitumor agent containing at least one compound selected from the group consisting of nerigoside, oleandrigenin, sarmentoside, oleaside A, oleandrin, 8β-hydroxy odoroside A, narciclasine, trans-dihydronarciclasine and bisdeoxynarciclasine is provided, this antitumor agent has an advantage of having an excellent therapeutic effect of tumor and less side effects. | |
| BCN1128 | Scutebarbatine A |
| 1. Scutebarbatine A shows significant antitumor effects on A549 cells in vivo and in vitro via mitochondria-mediated apoptosis by up-regulating expressions of caspase-3 and 9, and down-regulating Bcl-2. 2. Scutebarbatine A and barbatine A show a significant ability to protect cells against H2O2 with ED50 values of 5.0 and 16.8 uM, respectively. | |
| BCN1133 | Linderone |
| 1. Linderone A shows anticancer activity against A549 non-small cell lung cancer cells and PC-3 prostate adenocarcinoma cell line. | |
| BCN1146 | Nyssoside |
| 1. Nyssoside may have anticancer activity. | |
